A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Prostatic Neoplasms, Castration-Resistant
  • Taxoids

abstract

  • Combinations of cixutumumab or ramucirumab plus MP were feasible and associated with moderate toxicities in docetaxel-pretreated men with mCRPC. Of the two regimens, the ramucirumab regimen is worthy of further testing based on the observed cPFS relative to the historical control.

publication date

  • August 8, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5024789

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2015.05.019

PubMed ID

  • 26082390

Additional Document Info

start page

  • 1714

end page

  • 24

volume

  • 51

number

  • 13